Impact of Immunosuppressant Agents on Post Liver Transplant Patients with COVID-19

ABSTRACT

Background: It seems that transplant recipients are at high risk for severe COVID-19, especially in the presence of comorbidities and immunosuppression. This study aimed to determine the effects of previous treatment with immunosuppressants and received dosage and the risk of COVID-19 severity and mortality in liver transplant recipients in various post-transplantation phases in the Iranian population. Methods: This was a cross-sectional study conducted among 24 patients in the post liver transplant course, who were referred to two transplant centers (Imam Reza and Montaseriyeh hospitals) affiliated to Mashhad University of Medical Sciences, Mashhad, Iran, during 2020-2021. The demographic and clinical characteristics of the patients were recorded in a checklist, and the relation-ships between various variables were analyzed. Results: The majority of the post liver transplant patients (96%) were in the late phase of post-trans-plantation, and 8.3% of the cases expired. COVID-19 severity and mortality did not show a significant relationship with previous treatment with immunosuppressants and received dosage (P>0.05). In addition, there was no relationship between the symptoms of COVID-19 and immunosuppres-sant dosages, except for a headache. No significant correlation was found between immunosuppres-sants dosage and laboratory findings, and only prednisolone dosage was found to be correlated with heart rate (r=-0.62, P=0.03), BUN (r=-0.84, P=0.002), and D-dimer (r=-0.72, P=0.01). Conclusion: Severe SARS-CoV-2 infection was reported in the majority of liver transplant recipi-ents. The severity of COVID-19 was not related to previous treatment with immunosuppressants and received dosage.